February 4, 2011

BG Medicine Announces Pricing of Initial Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)-- BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company. The shares are expected to begin trading today on the NASDAQ Global Market under the ticker symbol "BGMD." In addition, the underwriters have been granted a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

Lazard Capital Markets LLC is acting as the sole bookrunning manager for the initial public offering, and Baird and Cowen and Company are acting as co-managers.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on February 3, 2011. This offering is being made solely by means of a written prospectus, a copy of which may be obtained from Lazard Capital Markets LLC by mail at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention: Syndicate Department, or by calling toll-free (800) 542-0970.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.

BG Medicine
Michael W. Rogers, 781-890-1199
EVP & Chief Financial Officer

Source: BG Medicine

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 BG Medicine, Inc.